HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by TROPÉ, C. Search for Related Content PubMed PubMed Citation Articles by TROPÉ, C.

Melphalan With and Without Doxorubicin in Advanced Ovarian Cancer

From the Swedish Cooperative Ovarian Cancer Study Group, Departments of Gynecologic Oncology of Lund, Göteborg, Orebro, Linköping, Stockholm, Uppsala, and Umed, Sweden.

Abstract

In October 1978, the Swedish Cooperative Ovarian Cancer Study Group started a randomized comparison of doxorubicin 40 mg/m² and melphalan 0.4 mg/kg with melphalan 1 mg/kg every four weeks in International Federation of Gynecology and Obstetrics (FIGO) stages III and IV ovarian cancer of serous and anaplastic histology. One hundred sixty-eight patients entered the study, and 148 were evaluable at five years or longer. All had residual tumors larger than 10 cm, with appropriate stratification according to stage, histologic grade, and age. Definition of response was according to World Health Organization (WHO) criteria except that we required three months' regression of all clinically detectable tumors instead of one month. Seventy-three women treated with doxorubicin plus melphalan had a significantly higher response rate than 75 patients treated with melphalan alone (54.7 versus 26.7%; P < .0001), median duration of response (13.0 versus 7.3 months; P < .0057), and median survival time (18.5 versus 10.5 months; P< .0001). Combined treatment produced significantly more complete remissions than single-agent therapy (30 versus 6.7%; P < .001). At 60 months, ten patients were alive in the doxorubicin plus melphalan group, compared with three in the melphalan group. Temporary bone marrow depression was significantly more frequent in the melphalan-treated patients, but subjective side effects were the same in both groups.

This article has been cited by other articles:

				M. Hod and Y. Yogev Goals of Metabolic Management of Gestational Diabetes: Is it all about the sugar? Diabetes Care, July 1, 2007; 30(Supplement_2): S180 - S187. [Full Text] [PDF]

				M. B. Landon, E. Thom, C. Y. Spong, M. Carpenter, L. Mele, F. Johnson, J. Tillinghast, G. Anderson, and For the Maternal-Fetal Medicine Units Network, The The National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit Network Randomized Clinical Trial in Progress: Standard therapy versus no therapy for mild gestational diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S194 - S199. [Full Text] [PDF]